Maria R. Calaminici

Charterhouse Square
London, ENG, United Kingdom

Last Updated: 09/26/2026

Save publications for later
Sign Up
Not sure about your diagnosis?
Check Your Symptoms
Found 47 publications

Practical implications of the World Health Organization Reporting System for Lymph Node, Spleen, and Thymus Cytopathology: Categories and ancillary testing for subtyping of hematolymphoid tumors on FNA biopsy cytopathology using a pattern-based approach.

Practical implications of the World Health Organization Reporting System for Lymph Node, Spleen, and Thymus Cytopathology: Categories and ancillary testing for subtyping of hematolymphoid tumors on FNA biopsy cytopathology using a pattern-based approach.

Journal: Cancer cytopathology
Published: October 12, 2025

TRBC1/TRBC2 Immunophenotyping Provides Added Value During the Diagnostic Workup of T-Cell Lymphoma.

TRBC1/TRBC2 Immunophenotyping Provides Added Value During the Diagnostic Workup of T-Cell Lymphoma.

Journal: EJHaem
Published: July 11, 2025

The World Health Organization Reporting System for Lymph Node, Spleen, and Thymus Cytopathology: Part 1 - Lymph Node.

The World Health Organization Reporting System for Lymph Node, Spleen, and Thymus Cytopathology: Part 1 - Lymph Node.

Journal: Acta cytologica
Published: July 04, 2025

CREBBP histone acetyltransferase domain mutations predict response to mTOR inhibition in relapsed/refractory follicular lymphoma.

CREBBP histone acetyltransferase domain mutations predict response to mTOR inhibition in relapsed/refractory follicular lymphoma.

Journal: British journal of haematology
Published: April 22, 2024

Investigator choice of standard therapy versus sequential novel therapy arms in the treatment of relapsed follicular lymphoma (REFRACT): study protocol for a multi-centre, open-label, randomised, phase II platform trial.

Investigator choice of standard therapy versus sequential novel therapy arms in the treatment of relapsed follicular lymphoma (REFRACT): study protocol for a multi-centre, open-label, randomised, phase II platform trial.

Journal: BMC cancer
Published: February 14, 2024

Impact of MYC and BCL2 double expression on outcomes in primary CNS lymphoma: a UK multicenter analysis.

Impact of MYC and BCL2 double expression on outcomes in primary CNS lymphoma: a UK multicenter analysis.

Journal: Blood advances
Published: August 15, 2023

Digital Examination of LYmph node CYtopathology Using the Sydney system (DELYCYUS): An international, multi-institutional study.

Digital Examination of LYmph node CYtopathology Using the Sydney system (DELYCYUS): An international, multi-institutional study.

Journal: Cancer cytopathology
Published: February 05, 2023

Genetic and Microenvironment Features Do Not Distinguish Follicular Lymphoma Patients Requiring Immediate or Deferred Treatment.

Genetic and Microenvironment Features Do Not Distinguish Follicular Lymphoma Patients Requiring Immediate or Deferred Treatment.

Journal: HemaSphere
Published: October 27, 2022

Lack of reproducibility of histopathological features in MYC-rearranged large B cell lymphoma using digital whole slide images: a study from the Lunenburg lymphoma biomarker consortium.

Lack of reproducibility of histopathological features in MYC-rearranged large B cell lymphoma using digital whole slide images: a study from the Lunenburg lymphoma biomarker consortium.

Journal: Histopathology
Published: August 09, 2022

PDL1 shapes the classical Hodgkin lymphoma microenvironment without inducing T-cell exhaustion.

PDL1 shapes the classical Hodgkin lymphoma microenvironment without inducing T-cell exhaustion.

Journal: Haematologica
Published: July 11, 2022

Genomic and microenvironmental landscape of stage I follicular lymphoma, compared with stage III/IV.

Genomic and microenvironmental landscape of stage I follicular lymphoma, compared with stage III/IV.

Journal: Blood advances
Published: June 24, 2022

Longitudinal expression profiling identifies a poor risk subset of patients with ABC-type diffuse large B-cell lymphoma.

Longitudinal expression profiling identifies a poor risk subset of patients with ABC-type diffuse large B-cell lymphoma.

Journal: Blood advances
Published: March 18, 2022
Showing 1-12 of 47

Last Updated: 09/26/2026